Effects of switching to the Tobacco Heating System 2.2 menthol, smoking abstinence, or continued cigarette smoking on biomarkers of exposure: A randomized, controlled, open-label, multicenter study in sequential confinement and ambulatory settings (Part 1)

Nicotine and Tobacco Research

Volumn 20, Issue 2, 2018, Pages 161-172

  Lüdicke, Frank ^a   Picavet, Patrick ^a   Baker, Gizelle ^a   Haziza, Christelle ^a   Poux, Valerie ^a   Lama, Nicola ^a   Weitkunat, Rolf ^a  

^a Philip Morris Products SA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYPROPYLMERCAPTURIC ACID; 4 [METHYLNITROSAMINO] 1 [3 PYRIDYL] 1 BUTANOL; ACETYLCYSTEINE; BIOLOGICAL MARKER; BUTANOL; CARBOXYHEMOGLOBIN; CYTOCHROME P450 1A2; MONOHYDROXYBUTENYL MERCAPTURIC ACID; NICOTINE; S PHENYLMERCAPTURIC ACID; UNCLASSIFIED DRUG; ANTIPRURITIC AGENT; MENTHOL;

ADULT; AGED; AMBULATORY CARE; AMES TEST; ARTICLE; CIGARETTE SMOKING; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FEMALE; HOSPITAL ADMISSION; HUMAN; HUMAN PUFFING TOPOGRAPHY; INTERMETHOD COMPARISON; JAPANESE (PEOPLE); MALE; MULTICENTER STUDY; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT PARAMETERS; SAFETY; SMOKING; SMOKING CESSATION; SMOKING DEVICE; SPIROMETRY; ANALYSIS; BLOOD; BREATH ANALYSIS; CLINICAL TRIAL; DEVICES; ENVIRONMENTAL EXPOSURE; HARM REDUCTION; HEATING; METHODOLOGY; MIDDLE AGED; PROCEDURES; PSYCHOLOGY; SMOKING PREVENTION; STATISTICS AND NUMERICAL DATA; TOBACCO; URINE; YOUNG ADULT;

ADULT; AGED; ANTIPRURITICS; BIOMARKERS; BREATH TESTS; CIGARETTE SMOKING; ENVIRONMENTAL EXPOSURE; FEMALE; HARM REDUCTION; HEATING; HUMANS; MALE; MENTHOL; MIDDLE AGED; RESEARCH DESIGN; SMOKING CESSATION; SMOKING PREVENTION; TOBACCO PRODUCTS; YOUNG ADULT;

EID: 85040536917     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/ntw287     Document Type: Article

References (41)

1. Royal College of Physicians. Harm Reduction in Nicotine Addiction: Helping People Who Can't Quit. A Report by the Tobacco Advisory Group of the Royal College of Physicians. London, UK: Royal College of Physicians; 2007
2. WHO Study Group, Ashley DL, Burns D, et al. The Scientific Basis of Tobacco Product Regulation: Report of a WHO Study Group. Technical Report Series, No 945. Geneva, Switzerland: World Health Organization; 2007
3. Zeller M, Hatsukami D. The strategic dialogue on tobacco harm reduction: a vision and blueprint for action in the US. Tob Control. 2009;18(4):324-
4. Gilmore AB, Britton J, Arnott D, Ashcroft R, Jarvis MJ. The place for harm reduction and product regulation in UK tobacco control policy. J Public Health (Oxf). 2009;31(1):3-10. doi:10.1093/pubmed/fdn105
5. FDA (Food and Drug Administration). Guidance for Industry-Modified Risk Tobacco Product Applications-Draft Guidance 2012. www.fda.gov/downloads/ TobaccoProducts/GuidanceComplianceRegulatoryInformation/ UCM297751.pdf. Accessed February 01, 2017
6. Institute of Medicine (IOM). Scientific Standards for Studies on Modified Risk Tobacco Products. Washington, DC: The National Academies Press; 2012
7. Ludicke F, Baker G, Magnette J, Picavet P, Weitkunat R. Reduced Exposure to Harmful and Potentially Harmful Smoke Constituents With the Tobacco Heating System 2.1. Nicotine Tob Res. 2017;19(2):168-175. doi: 10.1093/ntr/ntw164
8. Roethig HJ, Kinser RD, Nelson BL, Oey J, Wang N. Short term clinical exposure evaluation of conventional and electrically heated cigarettes. Poster presented at the American College of Clinical Pharmacology Meeting; 2002; San Francisco, CA
9. Roethig HJ, Kinser RD, Lau RW, Walk RA, Wang N. Short-term exposure evaluation of adult smokers switching from conventional to firstgeneration electrically heated cigarettes during controlled smoking. J Clin Pharmacol. 2005;45(2):133-145
10. Roethig HJ, Zedler BK, Kinser RD, Feng S, Nelson BL, Liang Q. Shortterm clinical exposure evaluation of a second-generation electrically heated cigarette smoking system. J. Clin. Pharmacol. 2007;47(4):518-530. doi:10.1177/0091270006297686
11. Martin Leroy C, Jarus-Dziedzic K, Ancerewicz J, Lindner D, Kulesza A, Magnette J. Reduced exposure evaluation of an electrically heated cigarette smoking system. Part 7: a one-month, randomized, ambulatory, controlled clinical study in Poland. Regul Toxicol Pharmacol. 2012;64; (2 suppl):S74-S84. doi:10.1016/j.yrtph.2012.08.006
12. Tricker AR, Jang IJ, Martin Leroy C, Lindner D, Dempsey R. Reduced exposure evaluation of an electrically heated cigarette smoking system. Part 4: eight-day randomized clinical trial in Korea. Regul Toxicol Pharmacol. 2012;64(2 suppl):S45-S53. doi:10.1016/j.yrtph.2012.08.013
13. Tricker AR, Kanada S, Takada K, et al. Reduced exposure evaluation of an electrically heated cigarette smoking system. Part 5: 8-day randomized clinical trial in Japan. Regul Toxicol Pharmacol. 2012;64(2):S54-S63. doi:10.1016/j.yrtph.2012.08.003
14. Tricker AR, Kanada S, Takada K, et al. Reduced exposure evaluation of an Electrically Heated Cigarette Smoking System. Part 6: 6-Day randomized clinical trial of a menthol cigarette in Japan. Regul. Toxicol. Pharmacol. 2012;64(2 Suppl):S64-73. doi:10.1016/j.yrtph.2012.08.007
15. Tricker AR, Stewart AJ, Leroy CM, Lindner D, Schorp MK, Dempsey R. Reduced exposure evaluation of an electrically heated cigarette smoking system. Part 3: eight-day randomized clinical trial in the UK. Regul Toxicol Pharmacol. 2012;64(2 suppl):S35-S44
16. Buchhalter AR, Eissenberg T. Preliminary evaluation of a novel smoking system: effects on subjective and physiological measures and on smoking behavior. Nicotine Tob Res. 2000;2(1):39-43
17. Buchhalter AR, Schrinel L, Eissenberg T. Withdrawal-suppressing effects of a novel smoking system: comparison with own brand, not own brand, and de-nicotinized cigarettes. Nicotine Tob Res. 2001;3(2):111-118. doi:10.1080/14622200110042636
18. Gonzalez-Suarez I, Martin F, Marescotti D, et al. In vitro systems toxicology assessment of a candidate modified risk tobacco product shows reduced toxicity compared to that of a conventional cigarette. Chem Res Toxicol. 2016;29(1):3-18. doi:10.1021/acs.chemrestox.5b00321
19. Phillips B, Veljkovic E, Boue S, et al. An 8-month systems toxicology inhalation/cessation study in Apoe-/-mice to investigate cardiovascular and respiratory exposure effects of a candidate modified risk tobacco product, THS 2.2, compared with conventional cigarettes. Toxicol Sci. 2016;149(2):411-432. doi:10.1093/toxsci/kfv243
20. van der Toorn M, Frentzel S, De Leon H, Goedertier D, Peitsch MC, Hoeng J. Aerosol from a candidate modified risk tobacco product has reduced effects on chemotaxis and transendothelial migration compared to combustion of conventional cigarettes. Food Chem Toxicol. 2015;86:81-87. doi:10.1016/j.fct.2015.09.016
21. Picavet P, Haziza C, Lama N, Weitkunat R, Ludicke F. Comparison of the pharmacokinetics of nicotine following single and ad Libitum use of a tobacco heating system or combustible cigarettes. Nicotine Tob Res. 2016;18(5):557-563. doi:10.1093/ntr/ntv220
22. World Medical Association (WMA). Ethical principles for medical research involving human subjects (Declaration of Helsinki). 2008. http://www.wma. net/en/30publications/10policies/b3/17c.pdf. Accessed February 01, 2017
23. ICH E6 (R1). Guideline for good clinical practice. 1996. www.ich.org/ fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_ Guideline.pdf. Accessed August 14, 2014
24. Kasza KA, Hyland AJ, Bansal-Travers M, et al. Switching between menthol and nonmenthol cigarettes: findings from the U.S. Cohort of the International Tobacco Control Four Country Survey. Nicotine Tob Res. 2014;16(9):1255-1265. doi:10.1093/ntr/ntu098
25. Lovreglio P, Barbieri A, Carrieri M, et al. Validity of new biomarkers of internal dose for use in the biological monitoring of occupational and environmental exposure to low concentrations of benzene and toluene. Int Arch Occup Environ Health. 2010;83(3):341-356. doi:10.1007/ s00420-009-0469-7
26. Imbriani M, Ghittori S, Cavalleri A. Significance of urinary concentrations of S-benzyl-N-acetylcysteine (S-BMA) in subjects exposed to toluene. G Ital Med Lav Ergon. 1999;21(4):329-333
27. Schettgen T, Musiol A, Alt A, Kraus T. Fast determination of urinary S-phenylmercapturic acid (S-PMA) and S-benzylmercapturic acid (S-BMA) by column-switching liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;863(2):283-292. doi:10.1016/j.jchromb.2008.01.024
28. Faber MS, Fuhr U. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin Pharmacol Ther. 2004;76(2):178-184. doi:10.1016/j.clpt.2004.04.003
29. Scherer G. Carboxyhemoglobin and thiocyanate as biomarkers of exposure to carbon monoxide and hydrogen cyanide in tobacco smoke. Exp Toxicol Pathol. 2006;58(2-3):101-124. doi:10.1016/j.etp.2006.07.001
30. Kado NY, Langley D, Eisenstadt E. A simple modification of the Salmonella liquid-incubation assay. Increased sensitivity for detecting mutagens in human urine. Mutat Res. 1983;121(1):25-32
31. Baker RS, Darnton-Hill I, Bonin AM, et al. Urine mutagenicity as an indicator of exposure to dietary mutagens formed during cooking of foods. Environ Health Perspect. 1986;67:147-152. https://www.ncbi.nlm.nih. gov/pubmed/?term=Environ+Health+Perspect.+1986%3B67%3A14 7%E2%80%93152
32. Pavanello S, Lupi S, Pulliero A, Gregorio P, Saia BO, Clonfero E. Mutagenic activity of overnight urine from healthy non-smoking subjects. Environ Mol Mutagen. 2007;48(2):143-150. doi:10.1002/em.20277
33. Gunes A, Dahl ML. Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms. Pharmacogenomics. 2008;9(5):625-637. doi:10.2217/14622416.9.5.625
34. MacLeod S, Sinha R, Kadlubar FF, Lang NP. Polymorphisms of CYP1A1 and GSTM1 influence the in vivo function of CYP1A2. Mutat Res. 1997;376(1-2):135-142
35. Matsuda K, Takahashi A, Middlebrooks CD, et al. Genome-wide association study identified SNP on 15q24 associated with bladder cancer risk in Japanese population. Hum Mol Genet. 2015;24(4):1177-1184. doi:10.1093/hmg/ddu512
36. Butler MA, Lang NP, Young JF, et al. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics. 1992;2(3):116-127
37. Lo Sasso G, Titz B, Nury C, et al. Effects of cigarette smoke, cessation and switching to a candidate modified risk tobacco product on the liver in Apoe(-/-) mice-a systems toxicology analysis. Inhal Toxicol. 2016;28(5):226-240. doi:10.3109/08958378.2016.1150368
38. Ogden MW, Marano KM, Jones BA, Morgan WT, Stiles MF. Switching from usual brand cigarettes to a tobacco-heating cigarette or snus: Part 2. Biomarkers of exposure. Biomarkers. 2015;20(6-7):391-403. doi:10.3109/1354750x.2015.1094134
39. Ogden MW, Marano KM, Jones BA, Stiles MF. Switching from usual brand cigarettes to a tobacco-heating cigarette or snus: Part 1. Study design and methodology. Biomarkers. 2015;20(6-7):382-390. doi: 10.3109/1354750x.2015.1094133
40. Miura N, Yuki D, Minami N, Kakehi A, Futamura Y. A study to investigate changes in the levels of biomarkers of exposure to selected cigarette smoke constituents in Japanese adult male smokers who switched to a noncombustion inhaler type of tobacco product. Regul. Toxicol. Pharmacol. 2015;71(3):498-506. doi:10.1016/j.yrtph.2015.02.007
41. Sakaguchi C, Kakehi A, Minami N, Kikuchi A, Futamura Y. Exposure evaluation of adult male Japanese smokers switched to a heated cigarette in a controlled clinical setting. Regul. Toxicol. Pharmacol. 2014;69(3):338-